Normal
The University is currently operating under normal conditions
Topple a paradigm. Uncover the unknown. Bold moves presume nothing – except innovation.
An undergraduate history class created a walking tour of Carolina’s campus that highlights the range of women’s experiences at the University.
Current hemophilia treatments have limitations for a significant number of patients. That’s why Carolina-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia, including the toughest cases.
The Carolina Postdoctoral Program for Faculty Diversity prepares scholars from different backgrounds for faculty careers.
Carolina's Intercollegiate Ethics Bowl Team will be facing off against 35 other schools for a national title this weekend. It is the team’s first time advancing to the national championship in over five years.
For two decades, Kenan-Flagler Business School’s Greg Hohn has used a theatrical technique to teach students about being human.
Convergent science is characterized by cross-disciplinary research teams created to tackle big problems and speed the application of new breakthroughs to commercialization. At Carolina, the Institute for Convergent Science is at the forefront of this pioneering framework.
Together with American studies professor Daniel Cobb, undergraduate students learned the meaning of hands-on research by getting their hands dirty. They planted a garden inspired by their transcriptions of the diary of one of the 20th century’s most influential American Indian writers and intellectuals.
Drug treatments for a rare form of cancer have eluded researchers for years. David Drewry’s work at the UNC Eshelman School of Pharmacy has scientists and survivors optimistic that big breakthroughs are within reach.